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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not Integra®
improves patient scar quality compared to standard autograft-allograft technique or splitthickness skin graft (STSG).
Study Design: Selective EBM review of two randomized controlled trials and one retrospective
study.
Data Sources: All studies were published in peer-reviewed journals found on PubMed.
Outcome(s) measured: The main outcome measured is patient scar quality, further defined by
scar pigmentation, pliability, height, irregularity, vascularity, range of movement, softness,
appearance, sensation, dryness, itch, and sweating.
Results: The study by Lagus, et al found that STSG had better scar outcomes than Integra® in
12 months. On the contrary, Branski, et al found a significant improvement in scars with the use
of Integra® at both 12 months and 18-24 months post burn injury. The study by Moiemen, et al
also showed statistical improvement in patient scars with Integra® two or more years after
treatment.
Conclusions: The three studies evaluated in this EBM review have conflicting results. Further
research is warranted to evaluate whether Integra® improves patient scar quality compared to
STSG.
Key Words: burn treatment, Integra, skin grafting, dermal substitute
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INTRODUCTION
Burns are defined as a traumatic injury to the skin and/or other tissues caused by extreme
heat, electrical discharge, friction, chemicals, or radiation. They are further classified by the
depth of the burn and the extent of the burn injury. Not only do burn injuries result in extensive
tissue and organ damage, but they can also leave tremendous cosmetic defects. Although recent
medical advances have greatly improved the morbidity and mortality of burn injuries, further
research is still being conducted on ways to achieve better functional and cosmetic (scar)
outcomes after a burn injury. This paper evaluates three studies that compare and evaluate two
methods currently used in the treatment of burn injuries and aims to determine if one method is
superior than the other.
Burn injuries are extremely common worldwide and in the United States. In fact, they are
a global public health problem and are identified as the fourth most common type of trauma
worldwide. 1 According to one systematic review, the average healthcare cost per burn patient is
$88,218 (range: $704-$717,306; median $44,024).1 In 2016, there were 486,000 burn injuries
that received medical treatment and 40,000 hospitalizations in the United States. 2
The usual methods used to treat burns include skin grafting, biosynthetic skin substitutes,
Integra® dermal regeneration, tissue expansion, and flap reconstruction. Integra® was the first
artificial skin substitute created to solve some of the shortcomings of skin grafting which include
limited skin availability, susceptibility to infections, and high incidences of hypertrophic
scarring.3 Some studies claimed the superiority of Integra® over skin grafts, however, most of
these claims were based on heterogenic studies and case reports. 3 The articles utilized in this
selective EBM review include two Randomized Controlled Trials and one Retrospective Study
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that aim to evaluate the effectiveness of Integra® in providing optimal cosmetic outcome versus
skin grafts.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not Integra®
improves patient scar quality compared to standard autograft-allograft technique or splitthickness skin graft (STSG).
METHODS
The population chosen for this review includes patients of all ages who have undergone
treatment with Integra® post burn injury. The results from these patients were then compared
against other patients or other sites that received standard autograft-allograft technique or splitthickness skin graft. The outcome that was measured is scar quality. This selective EBM review
includes two (2) Randomized Controlled Trials and one (1) Retrospective Study.
Keywords used in searches include ‘Integra’, ‘burn treatment’, ‘skin grafting’, and
‘dermal substitute’. Each article used in this selective EBM is published data and written in
English. All the research was done on PubMed and the articles were selected based on relevance
to the clinical question. Inclusion criteria: relevant primary articles published between 2006present that answer the clinical question. Exclusion criteria: articles that used a different method
of treatment for burn injuries and articles that did not measure or evaluate patient cosmetic (scar)
outcome after the use of Integra® post burn injury. Statistics reported or used include: P-value,
SD, and/or mean change from baseline.
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Table 1: Demographics & Characteristics of included studies
Study

Type

Lagus3
(2013)

RCT

#
Pts
10

Branski4
(2007)

RCT

20

Moiemen5
(2011)

Retrospective
Study

14

Age

Inclusion
Criteria
Age between
17 and 70
years; TBSA
(total burned
surface area) >
20%; Burns
located on the
anterior side
of the body;
Test areas
were deep
third-degree
burns
requiring
fascial
excision

Exclusion
Criteria
None
specified

W/D

Interventions

2

Integra®,
Cellonex,
Split
thickness
skin graft

Children
(age range
not
specified)

Severely
burned
children
admitted to
the Shriners
Hospital for
Children in
Galveston, TX
between
November
2001 and
March 2003;
Burn size ≥
50% TBSA
and ≥ 40%
TBSA fullthickness
burn; Patients
admitted
within 72 hrs
of injury;
Patients not
septic at
admission

None
specified

1

Integra®,
Standard
autograftallograft
technique

17-55yo

Fourteen (14)
patients who
had previously
undergone
standardized

None
specified

0

Integra®

17-70 yo
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two-stage scar
resurfacing
(reconstructio
n) using
Integra® more
than 2 years
before they
were assessed;
Patient ages
between 17 –
55 years old

OUTCOMES MEASURED
The outcome measured in this selective EBM review is the patient scar quality, further
characterized by scar pigmentation, pliability, height, irregularity, and vascularity in two of the
articles. In the third article, the patient scar quality was assessed based on range of movement,
softness, appearance, sensation, dryness, itch, and sweating. Outcomes were measured in each
article based on a scoring system as outlined in Table 2.
Table 2: Outcomes Scoring System
Scoring System

Outcomes
Measured

Evaluator

Scoring
Range

Lagus, et al3

Vancouver Scar
Scale

Branski, et al4

Hamilton Burn
Scar Scoring
System

Moiemen, et al5

Patient
Satisfaction
Questionnaire

Scar pigmentation,
pliability, height,
vascularity
Scar
height/thickness,
irregularity,
vascularity,
pigmentation
Range of
movement,
softness,
appearance,
sensation, dryness,
itch, sweating

Occupational
therapist

0 -13

Blinded
clinicians

0 -14

Patient

-10 - +10
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RESULTS
In the study by Lagus et al, the effectiveness of Integra® was compared against split
thickness skin graft (STSG) and Cellonex (viscose cellulose sponge). Ten patients from the
Helsinki Burn Center that met the inclusion criteria listed in Table 1 were chosen for the study.
Each of the ten patients had three test areas: one area covered by STSG, a second area covered
by Integra®, and a third area covered by Cellonex. The cosmetic outcomes of each test area were
then evaluated 3 months and 12 months later by an occupational therapist using the Vancouver
Scar Scale. The Vancouver Scar Scale has a scoring range of 0-13 and was specifically
developed to measure pigmentation (0-2), pliability (0-5), height (0-3), and vascularity (0-3) of a
scar post burn injury.6
Table 3: Vancouver Scar Scale6
Vascularity

Pigmentation
Pliability

Height

Scar Characteristic
Normal
Pink
Red
Purple
Normal
Hypopigmentation
Hyperpigmentation
Normal
Supple
Yielding
Firm
Ropes
Contracture
Flat
<2mm
2-5mm
>5mm
Total Score

Score
0
1
2
3
0
1
2
0
1
2
3
4
5
0
1
2
3
13

Data presented by the authors in the study by Lagus et al 3 include mean values and mean
change between 3 and 12 months in scar vascularity, pigmentation, pliability, and height. For this
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review, only the results for Integra® and STSG will be examined. Of note, in this study, lower
scores equal better scar outcomes, as detailed in Table 3. In 3 months, STSG had a mean value of
1.3 in pigmentation, 0.7 in pliability, 0 in height, and 0.5 in vascularity. In 12 months, STSG scar
pigmentation had a mean value of 0.4, pliability mean value of 0, height mean value 0.1, and
vascularity mean value of 0.3.3 These mean values show that in 12 months, test areas treated
with STSG showed improvement in all categories, except for scar height. 3 On the contrary, in 3
months, Integra® had a mean value of 0.4 in pigmentation, 1.3 in pliability, 0 in height, and 0.8
in vascularity. In 12 months, Integra® scored a 0.4 in pigmentation, 0.4 in pliability, 0.1 in
height, and 0.4 in vascularity.3 Unlike STSG, in 12 months, Integra® only showed improvement
in pliability and vascularity.3 In regards to mean values of total scores, STSG showed
improvement from 2.5 to 0.8 in 12 months, while Integra® had an overall improvement of 2.5 to
1.3 in 12 months. Overall, STSG scored better than Integra® in this study and found that
Integra® did not perform better than STSG.3
Table 4: Mean values and mean change at 3 and 12 months 3

STSG
Integra

Pigmentation
3 mos.
12 mos
1.3
0.4
0.4
0.4

Pliability
3 mos. 12 mos
0.7
0
1.3
0.4

Height
3 mos. 12 mos
0
0.1
0
0.1

Vascularity
3 mos. 12 mos
0.5
0.3
0.8
0.4

Total scores
3 mos 12 mos
2.5
0.8
2.5
1.3

*P-values were not reported in this study.

In the study by Branski et al4, patients were randomized to receive either Integra® or
STSG and respective burns scars were assessed using the Hamilton Burn-Scar Rating System.
This scoring system is based on scar height/thickness, irregularity, vascularity, and pigmentation.
The patient scars were photographed and assessed by blinded clinicians who were not involved
in the care of the patients. The scars were evaluated at 12 months and again at 18-24 months post
burn injury. Hamilton burns scar scores of Integra® was 5.4±1.7 at 12 months and 4.3±2.2 at 18-
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24 months with a p-value of .035. On the contrary, Hamilton burn scar scores of STSG was
7.7±2.6 at 12 months and 6.6±3.1 at 18-24 months with a p-value of .403. Calculations were
made using unpaired Student’s t-tests (Kolmogorov-Smirnov test), clinical significance was
accepted at p <.05 and statistical analysis were made using SigmaStat. Based on the assessments
made by the blinded clinicians, this study concluded that there was a significant improvement in
scars with the use of Integra® at both 12 months and 18-24 months post burn injury, while there
was no statistical improvement in burn scars with STSG.
Table 5: Hamilton Burn Scar Scores at 12 months and 18-24 months after injury 4
Integra®

Control

p-value

12 months

5.4±1.7

7.7±2.6

.003

18-24 months

4.3±2.2

6.6±3.1

.02

p-value

.035

.403

In the study by Moiemen et al5, fourteen patients who had previously received Integra®
more than two years earlier were asked to assess their scars using a visual analogue scale via a
patient questionnaire. The visual analogue scale ranged from -10 to +10, in which -10
represented deterioration, 0 represented no change, and +10 represented improvement. The
patients scored their scars based on seven characteristics, including, range of movement,
softness, appearance, sensation, dryness, itch, and sweating. Mean values and p-values are as
listed below in Table 6. As shown in Table 6, there was statistical improvement (p-value <.05)
with the use of Integra® in all categories except itch and sweating. The characteristics with the
highest mean % improvement include range of movement, softness, and appearance (p-value
<0.001) with mean % improvement of 39.2%, 44.6%, and 41.3% respectively. Sensation and
dryness also showed statistical improvement with mean % improvement of 14.6% and 13.8%

EBORAS, INTEGRA AND BURN SCAR OUTCOMES 9

and p-values 0.015 and 0.033 respectively. This statistical improvement supports the use of
Integra® in achieving optimal scar outcomes.
Table 6: Patient’s Self-Assessment of the Improvement of Their Scars with Mean Scores

Range of Movement
Softness
Appearance
Sensation
Dryness
Itch
Sweating

Mean % Improvement

p-value

39.2
44.6
41.3
14.6
13.8
3.8
0.00

<0.001
<0.001
<0.001
0.015
0.033
0.34
1

DISCUSSION
For many years, split thickness skin grafting has been the standard of care in treating full
thickness burns.7 Over the past two decades, techniques in skin grafting have improved
significantly from cutting grafts freehand with a large knife to the more current meshed splitthickness skin grafts harvested using a powered dermatome.7 Recent studies have shown that the
more recent skin grafting techniques appear to cause less keloid formation, contractures, and
ulcerations than previous techniques, however, there are still many limiting factors to skin
grafting, such as limited availability of native skin, risk of antigenicity with allografts, and poor
cosmetic outcomes, which have led to significant interest in bioengineered skin substitutes over
STSG.7
Integra® dermal regeneration template was one of the first bioengineered dermal
substitute that showed promise in overcoming the shortcomings of skin grafting. Integra® is a
bilayer dermal substitute with an outer layer and an inner layer. The outer layer consists of a
polysiloxane polymer with properties that help control moisture, limit bacterial invasion, and
provides protection against mechanical trauma.4,7 The inner layer (dermal replacement) consists
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of a highly porous scaffold made up of bovine collagen and chondroitin-6-sulfate, which helps
facilitate dermis regeneration.4,7 Although this dermal substitute has only been around for a few
years, Integra® has seemed to successfully reduce hospital stays, improve patient’s functional
outcomes, and provide better cosmetic outcomes. 4 In this selective EBM review, two randomized
controlled trials and one retrospective study were examined that compared the scar outcomes
with the use of Integra® versus the standard split thickness skin graft.
In the study by Lagus et al3, the authors concluded that Integra® did not provide better
scar quality in comparison to STSG 12 months after Integra® placement. In fact, it performed
the worst out of the three methods that were examined in the study. One reasoning for this that
the authors alluded to is the possibility that the Integra® template maturation may not have yet
been completed at 12 months and could have affected the results of the study.
The study by Branski et al4, on the other hand, concluded that Integra® had better scar
outcomes compared to STSG both at 12 months and 18-24 months post burn injury. This study
also stated that only did Integra® have better outcomes at 12 months, but scarring actually
improved significantly between 18-24 months after Integra® placement.
In the study performed by Moiemen et al5, patients were analyzed two or more years after
receiving Integra® treatment. These patients were given a patient satisfaction questionnaire
which allowed the patients to self-assess their scars. The study concluded that there was
significant statistical improvement in patient scar softness, appearance, range of movement,
sensation, and dryness two or more years post Integra® placement.
In the three studies addressed in the selective review, small sample size is a shared
limitation that could have affected the results and the validity of all three studies. There are also
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differences in population demographics, severity of burn injuries, and assessment techniques in
each of the studies, which could affect the generalizability of the data presented. Of note,
searching for applicable and valid studies to be used for this selective review was also limited
due to a very small number of prospective and randomized controlled studies available that
examined long-term outcomes of Integra® as treatment for burn injuries.
CONCLUSION
The studies presented in this selective EBM review had conflicting results. One of the
studies stated that Integra® does not improve patient scar outcomes compared to the standard
STSG, while the other two studies concluded that Integra® performed better compared to the
standard STSG. Of note, the two studies that concluded that Integra® improved patient scar
outcomes evaluated patients 18-24+ months after treatment. In future studies, it might be worth
evaluating a patient cohort who received treatment 18-24 months before assessment to ensure
that the Integra® template has undergone full maturation before scar evaluation and identify if
this influences results. Future studies should also include a patient cohort that are comparable
with similar demographics and burn severity, ideally in a randomized controlled double blinded
study.
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